Market capitalization | $21.48m |
Enterprise Value | $-76.83m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 6.17 |
P/B ratio (TTM) P/B ratio | 0.22 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-15.54m |
Free Cash Flow (TTM) Free Cash Flow | $-12.46m |
Cash position | $98.31m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Tenax Therapeutics, Inc. forecast:
4 Analysts have issued a Tenax Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
67%
67%
|
|
EBITDA | -16 -16 |
109%
109%
|
EBIT (Operating Income) EBIT | -16 -16 |
109%
109%
|
Net Profit | -15 -15 |
107%
107%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.
Head office | United States |
CEO | Christopher Giordano |
Employees | 5 |
Founded | 1967 |
Website | www.tenaxthera.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.